Cantor Fitzgerald Comments on AVITA Medical FY2026 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Cantor Fitzgerald issued their FY2026 earnings estimates for AVITA Medical in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($0.23) per share for the year. The consensus estimate for AVITA Medical’s current full-year earnings is ($0.95) per share.

Separately, D. Boral Capital restated a “buy” rating and issued a $19.00 price objective on shares of AVITA Medical in a research note on Friday, June 6th.

AVITA Medical Price Performance

Shares of AVITA Medical stock opened at $5.80 on Wednesday. The firm has a fifty day simple moving average of $7.74 and a 200-day simple moving average of $9.37. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39. AVITA Medical has a 1-year low of $5.46 and a 1-year high of $14.16. The stock has a market capitalization of $153.32 million, a price-to-earnings ratio of -2.43 and a beta of 1.55.

AVITA Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.14). The business had revenue of $18.51 million during the quarter, compared to analyst estimates of $33.15 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%.

Institutional Trading of AVITA Medical

A number of institutional investors and hedge funds have recently modified their holdings of RCEL. BNP Paribas Financial Markets acquired a new position in AVITA Medical during the 4th quarter valued at $38,000. CWM LLC raised its stake in AVITA Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company’s stock valued at $40,000 after purchasing an additional 4,508 shares during the last quarter. GAMMA Investing LLC raised its stake in AVITA Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock valued at $52,000 after purchasing an additional 5,566 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in AVITA Medical during the 1st quarter valued at $53,000. Finally, Russell Investments Group Ltd. raised its stake in AVITA Medical by 48.0% during the 4th quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock valued at $92,000 after purchasing an additional 2,324 shares during the last quarter. 27.66% of the stock is currently owned by institutional investors and hedge funds.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.